Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score 5.68
- Piotroski Score 7.00
- Grade Buy
- Symbol (CRS)
- Company Carpenter Technology Corporation
- Price $179.17
- Changes Percentage (2.09%)
- Change $3.67
- Day Low $177.10
- Day High $182.52
- Year High $182.52
Carpenter Technology Corporation engages in the manufacture, fabrication, and distribution of specialty metals in the United States, Europe, the Asia Pacific, Mexico, Canada, and internationally. It operates in two segments, Specialty Alloys Operations and Performance Engineered Products. The company offers specialty alloys, including titanium alloys, powder metals, stainless steels, alloy steels, and tool steels, as well as additives, and metal powders and parts. It serves aerospace, defense, medical, transportation, energy, industrial, and consumer markets. The company was founded in 1889 and is headquartered in Philadelphia, Pennsylvania.
- Last Earnings 10/10/2024
- Ex-Dividend for 5/16 Dividend 10/22/2024
- Dividend Payable 12/05/2024
- Today N/A
- Next Earnings (Estimated) 01/23/2025
- Fiscal Year End N/A
- Average Stock Price Target $144.00
- High Stock Price Target $144.00
- Low Stock Price Target $144.00
- Potential Upside/Downside N/A
- Consensus Rating Neutral
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) $2.63
- Trailing P/E Ratio 39.62
- Forward P/E Ratio 39.62
- P/E Growth 39.62
- Net Income $186.50 M
Income Statement
Quarterly
Annual
Latest News of CRS
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
CRISPR Therapeutics AG (CRSP): Among ARK Invest's Top Stock Picks for 2024
ARK Invest, led by Catherine Wood, is an American investment firm managing ETFs with $6.7 billion in assets. Despite recent challenges, Wood remains optimistic about the fund's performance, expecting ...
By Yahoo! Finance | 1 day ago -
News Flash: Analysts Just Made A Meaningful Upgrade To Their Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Forecasts
Analysts have upgraded Aclaris Therapeutics' revenue forecasts, leading to a 21% rise in share price. Despite expecting a decline in sales in 2025, analysts are more optimistic, reducing loss estimate...
By Yahoo! Finance | 6 days ago -
Is CRISPR Therapeutics (CRSP) a Promising Gene Editing Stock?
We recently listed the 10 Most Promising Gene Editing Stocks, including CRISPR Therapeutics AG. The pharmaceutical industry is driven by innovation in gene therapy and editing, with CRISPR technology ...
By Yahoo! Finance | 2 weeks ago
